Cargando…
Rapid infusion rituximab is well tolerated in patients with primary CNS lymphoma
AIM: To establish the safety and feasibility of rapidly infusing rituximab over 90 min in patients with primary CNS lymphoma (PCNSL). PATIENTS & METHODS: We retrospectively reviewed all patients with PCNSL who received rapid rituximab infusions (RRI) from January 2016 to January 2017. Primary en...
Autores principales: | Modelevsky, Lisa, Tizon, Richard, Reiss, Samantha N, Smith, Marcel, Garonce, Rachel, Kaley, Thomas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Future Medicine Ltd
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6200062/ https://www.ncbi.nlm.nih.gov/pubmed/30221993 http://dx.doi.org/10.2217/cns-2018-0001 |
Ejemplares similares
-
Is more better? Increased doses of high dose methotrexate and addition of rituximab is associated with improved outcomes in a large primary CNS lymphoma cohort
por: Yerram, Prakirthi, et al.
Publicado: (2023) -
Rapid Infusion Rituximab for Maintenance Therapy: Is It Feasible?
por: Patel, Jolly, et al.
Publicado: (2013) -
Retrospective review of safety and efficacy of programmed cell death-1 inhibitors in refractory high grade gliomas
por: Reiss, Samantha N., et al.
Publicado: (2017) -
Salvage chemotherapy with R-BAD (rituximab, bendamustine, cytarabine, and dexamethasone) for the treatment of relapsed primary CNS lymphoma
por: Cho, Min-Seok, et al.
Publicado: (2016) -
Primary CNS Lymphoma
por: Phillips, Elizabeth H., et al.
Publicado: (2014)